Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bayer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,187 result(s) found for: Bayer. Displaying page 1 of 60.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-003618-15 Sponsor Protocol Number: 20321 Start Date*: 2020-06-25
    Sponsor Name:Bayer Consumer Care AG
    Full Title: An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies
    Medical condition: Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) LT (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) PT (Completed) DE (Trial now transitioned) LV (Trial now transitioned) BG (Trial now transitioned) AT (Completed) EE (Completed) SK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000501-36 Sponsor Protocol Number: BAY63-2521/18694 Start Date*: 2016-06-09
    Sponsor Name:Bayer HealthCare
    Full Title: An open-label, multi-national, multi-center, single-arm, uncontrolled, long-term extension study of orally administered riociguat in patients with symptomatic pulmonary arterial hypertension (PAH) ...
    Medical condition: Hypertension, Pulmonary
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003655-37 Sponsor Protocol Number: 19764 Start Date*: 2019-09-23
    Sponsor Name:Bayer Consumer Care AG
    Full Title: Post-marketing investigation (PMI) to assess safety and efficacy of Jivi® (BAY 94-9027) treatment in patients with hemophilia A
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000962-76 Sponsor Protocol Number: 17992 Start Date*: 2015-09-22
    Sponsor Name:Bayer AG
    Full Title: Single-dose study testing a rivaroxaban granules for oral suspension formulation in children from 2 months to 12 years with previous thrombosis
    Medical condition: Thrombosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10043607 Thrombosis PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) IE (Completed) ES (Completed) FI (Completed) HU (Completed) SE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000952-32 Sponsor Protocol Number: BAY86-4873/16078 Start Date*: 2015-09-24
    Sponsor Name:Bayer HealthCare AG
    Full Title: Open-label, multi-center study to evaluate the safety, efficacy, and plasma gadolinium concentrations after an intravenous injection of 0.1 mL/kg body weight Eovist/Primovist for enhanced magnetic ...
    Medical condition: Magnetic Resonance Imaging
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10072304 Nuclear magnetic resonance imaging liver PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000737-40 Sponsor Protocol Number: BAY12-8039/11826 Start Date*: 2012-02-20
    Sponsor Name:Bayer HealthCare Pharmaceuticals
    Full Title: Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients
    Medical condition: No medical condition specified as the purpose of this study is to describe the pharmacokinetics of moxifloxacin in children for future antibiotic treatment.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004622-18 Sponsor Protocol Number: BAYO9867/100201 Start Date*: 2015-01-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of either ciprofloxacin (either as oral suspension, oral tablets or sequential IV followe...
    Medical condition: Infectious Diseases
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001759-10 Sponsor Protocol Number: Bay63-2521/16719 Start Date*: 2014-01-03
    Sponsor Name:Bayer AG
    Full Title: Open-label, international, multicenter, single-arm, uncontrolled, phase IIIb study of riociguat in patients with pulmonary arterial hypertension (PAH) who demonstrate an insufficient response to tr...
    Medical condition: Hypertension, Pulmonary
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) IT (Completed) BE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000566-22 Sponsor Protocol Number: BAY59-7939/14374 Start Date*: 2014-07-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: 30-day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosis
    Medical condition: Venous Thrombosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) IT (Completed) ES (Completed) AT (Completed) NL (Completed) BE (Completed) GB (Completed) FR (Completed) HU (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-024332-42 Sponsor Protocol Number: BAY63-2521/13605 Start Date*: 2014-04-10
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmon...
    Medical condition: pulmonary hypertension associated with idiopathic interstitial pneumonias
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) BE (Completed) GB (Completed) PT (Completed) DK (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004612-10 Sponsor Protocol Number: BAY86-5300/91772 Start Date*: 2015-01-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of an oral contraceptive preparation YAZ (drospirenone 3 mg / ethinylestradiol 20 µg) for 6 tre...
    Medical condition: Acne Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023003-96 Sponsor Protocol Number: BAY86-4875/91741 Start Date*: 2012-04-25
    Sponsor Name:Bayer HealthCare AG
    Full Title: Open-label, multicenter, pharmacokinetic, and safety study in children (term newborn infants to 23 months of age) undergoing a contrast-enhanced MRI with an intravenous injection of 0.1 mmol/kg BW ...
    Medical condition: Pediatric subjects aged <2 years (term newborn infants to toddlers 23 months of age inclusive) scheduled to undergo routine gadolinium-enhanced MRI of any body region
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001067-36 Sponsor Protocol Number: 18588 Start Date*: 2016-11-21
    Sponsor Name:Bayer AG
    Full Title: A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosp...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) NL (Completed) DK (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000565-47 Sponsor Protocol Number: BAY59-7939/14372 Start Date*: 2014-07-25
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with...
    Medical condition: Venous Thrombosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) GB (Completed) PL (Completed) IE (Completed) FR (Completed) FI (Completed) HU (Completed) SE (Completed) SK (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002611-99 Sponsor Protocol Number: 20090 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer AG
    Full Title: Open-label, randomized, two–arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy ...
    Medical condition: Retinopathy of prematurity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) NL (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) SK (Completed) AT (Completed) BG (Completed) PL (Completed) ES (Completed) HU (Completed) LT (Completed) EE (Completed) LV (Completed) GR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2005-005103-41 Sponsor Protocol Number: 8200 Start Date*: 2005-12-05
    Sponsor Name:Anne Mette Hvas
    Full Title: Clot formation and clot stability in severe haemophilia A - effect of recombinant factor VIII and tranexamic acid.
    Medical condition: Severe haemophilia A
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002385-74 Sponsor Protocol Number: BAY59-7939/17618 Start Date*: 2015-04-24
    Sponsor Name:Bayer HealthCare AG
    Full Title: 7-day study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children from birth to less than 6 months with catheter-related arterial or venous ...
    Medical condition: Catheter related venous or arterial thrombosis
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) DE (Completed) NL (Completed) PL (Completed) FR (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005305-20 Sponsor Protocol Number: BAYH6689/15833 Start Date*: 2015-02-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Pilot Self Selection Trial of an Extended-Release Over-the-Counter Analgesic
    Medical condition: Pain
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005316-41 Sponsor Protocol Number: BAYH6689/15647 Start Date*: 2015-02-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: An Actual Use Trial In A Simulated OTC Environment of an Extended-Release Over-the-Counter NSAID
    Medical condition: Pain
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005268-13 Sponsor Protocol Number: BAYH6689/13129 Start Date*: 2015-02-05
    Sponsor Name:Bayer HealthCare AG
    Full Title: An Open Label, Actual Use Study in Consumers Taking an Extended-Release Over the Counter NSAID in a Naturalistic Setting
    Medical condition: Pain
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 11 15:29:52 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA